EHA 2021 | Narsoplimab increases platelets and decreases LDH in TA-TMA
Eleni Gavriilaki, MD, PhD, National and Kapodistrian University of Athens, Athens, Greece, shares an update on narsoplimab, a novel compliment inhibitor targeting mannan-binding lectin-associated serine protease-2 (MASP-2), which is being investigated for the treatment of transplant-associated thrombotic microangiopathy (TA-TMA). Dr Gavriilaki reports that a single-arm Phase II trial (NCT02222545) of narsoplimab in adult TA-TMA patients demonstrated promising results with an increase in platelet count and a decrease in LDH. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Transcript (edited for clarity)
Narsoplimab is a novel compliment inhibitor attacks MASP-2, and in this year’s EHA 2021, there is an abstract presented by the first author, Dr Perales and the authors, showing a single arm pivotal trial in adult TA-TMA patients.
Actually, these results are very encouraging, showing increase in platelet count and decrease in the values of LDH in this patient population without any safety concerns regarding narsoplimab and confirm once again the safety and the efficacy of compliment inhibitors in adult TA-TMA...
Narsoplimab is a novel compliment inhibitor attacks MASP-2, and in this year’s EHA 2021, there is an abstract presented by the first author, Dr Perales and the authors, showing a single arm pivotal trial in adult TA-TMA patients.
Actually, these results are very encouraging, showing increase in platelet count and decrease in the values of LDH in this patient population without any safety concerns regarding narsoplimab and confirm once again the safety and the efficacy of compliment inhibitors in adult TA-TMA. And I think, opening the way for their clinical use in everyday practice.
Read more...
Disclosures
Eleni Gavriilaki, MD, PhD, has participated in consultancy work with Alexion and Omeros Corporation.
